8C

Cocrystal Pharma IncDUS Cocrystal Stock Report

Last reporting period 30 Sep, 2023

Updated 22 Nov, 2024

Last price

Market cap $B

0.018

Micro

Exchange

XDUS - Boerse Duesseldorf

8CC.DU Stock Analysis

8C

Uncovered

Cocrystal Pharma Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.018

Dividend yield

Shares outstanding

8.143 B

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. The company is headquartered in Bothell, Washington and currently employs 13 full-time employees. The company went IPO on 2018-03-12. The firm focuses on developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. The firm focuses on treating influenza virus, coronavirus, hepatitis C virus (HCV) and norovirus infections by discovering and developing drug candidates targeting the viral replication process. The firm uses computational methods to screen and design product candidates using cocrystal structural information. Its development pipeline includes CC-31244 and CC-42344. The Company’s CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a PB2 inhibitor for the treatment of influenza A infection. Its pipeline also includes CDI-45205 for the treatment of coronavirus. The company has also developed chemical libraries consisting of non-nucleoside inhibitors, metal-binding inhibitors, and drug-like fragments.

View Section: Eyestock Rating